SEARCH

SEARCH BY CITATION

References

  • 1
    Raffini L, Huang YS, Feudtner C. Dramatic increase in venous thromboembolism in children’s hospitals in the United States from 2001 to 2007. Pediatrics 2009; 124: 10018.
  • 2
    Massicotte P, Julian JA, Gent M, Marzinotto V, Szechtman B, Chan AK, Andrew M. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thromb Res 2003; 109: 1018.
  • 3
    Massicotte P, Julian JA, Marzinotto V, Gent M, Shields K, Chan AK, Kohne S, Shepherd S, Bacher P, Andrew M. Dose-finding and pharmacokinetic profiles of prophylactic doses of a low molecular weight heparin (reviparin-sodium) in pediatric patients. Thromb Res 2003; 109: 939.
  • 4
    Mitchell L, Andrew M, Hanna K, Abshire T, Halton J, Cherrick I, Desai S, Mahoney D, McCusker P, Chait P, Abdolell M, Mikulis D. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost 2003; 90: 23544.
  • 5
    Ruud E, Holmstrom H, De Lange C, Hogstad EM, Wesenberg F. Low-dose warfarin for the prevention of central line-associated thromboses in children with malignancies a randomized, controlled study. Acta Paediatr 2006; 95: 10539.
  • 6
    Kuhle S, Massicotte P, Dinyari M, Vegh P, Mitchell D, Marzinotto V, Chan A, Pieniaszek H, Mitchell LG. Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events. Thromb Haemost 2005; 94: 116471.
  • 7
    Kuhle S, Eulmesekian P, Kavanagh B, Massicotte P, Vegh P, Mitchell LG. A clinically significant incidence of bleeding in critically ill children receiving therapeutic doses of unfractionated heparin: a prospective cohort study. Haematologica 2007; 92: 2447.
  • 8
    Young G, Tarantino MD, Wohrley J, Weber LC, Belvedere M, Nugent DJ. Pilot dose-finding and safety study of bivalirudin in infants <6 months of age with thrombosis. J Thromb Haemost 2007; 5: 16549.
  • 9
    Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 6924.
  • 10
    Schulman S, Angeras U, Bergqvist D, Eriksson B, Lassen MR, Fisher W. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010; 8: 2024.
  • 11
    European Medicines Agency. Note for guidance on clinical investigation of medicinal products for the treatment of venous thromboembolic disease. http://www.ema.europa.eu/pdfs/human/ewp/056398en.pdf. Accessed 16 December 1999.
  • 12
    European Medicines Agency. Guideline on clinical investigation of medicinal products for the prophylaxis of venous thromboembolic risk in non-surgical patients. http://www.tga.gov.au/docs/pdf/euguide/ewp/623504en.pdf. Accessed 30 March 2006.
  • 13
    European Medicines Agency. Guideline on clinical investigation of medicinal products for prophylaxis of high intra- and post-operative venous thromboembolic risk. http://www.ema.europa.eu/pdfs/human/ewp/70798en.pdf. Accessed 20 April 2007.
  • 14
    Goldenberg NA, Durham JD, Knapp-Clevenger R, Manco-Johnson MJ. A thrombolytic regimen for high-risk deep venous thrombosis may substantially reduce the risk of postthrombotic syndrome in children. Blood 2007; 110: 4553.
  • 15
    Kuhle S, Koloshuk B, Marzinotto V, Andrew M, Chan A, Abdolell M, Mitchell L. A cross-sectional study evaluating post-thrombotic syndrome in children. Thromb Res 2003; 111: 22733.
  • 16
    Neuner B, von Mackensen S, Krumpel A, Manner D, Friefeld S, Nixdorf S, Fruhwald M, Deveber G, Nowak-Gottl U. Health-related quality of life in children and adolescents with stroke, self-reports, and parent/proxies reports: cross-sectional investigation. Ann Neurol 2011; 70: 708.